Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. (Q39172509)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 June 2014

Language	Label	Description	Also known as
English	Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.	scientific article published on 17 June 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

phase III clinical trial

0 references

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

Richard A Hubner

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Janusz A. Jankowski

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Jane M. Blazeby

3

object named as

Jane M Blazeby

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Susan J Dutton

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

David R Ferry

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Haider Abbas

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Asa Dahle-Smith

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Wasat Mansoor

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Joyce Thompson

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Mark Harrison

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Anirban Chatterjee

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Stephen Falk

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Angel Garcia-Alonso

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

David W Fyfe

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Tina Gamble

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Lynnda Peachey

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Mina Davoudianfar

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Sarah R Pearson

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Patrick Julier

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Rachel Kerr

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Russell D Petty

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

publication date

17 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

894-904

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Global patterns of cancer incidence and mortality rates and trends

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastroesophageal cancers: progress and problems

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Esophageal cancer: a critical evaluation of systemic second-line therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Unmet needs and challenges in gastric cancer: the way forward

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70024-5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39172509&oldid=1450159543"